GT Biopharma fails Nasdaq independent director rule; cure until Nov 2022

GT Biopharma, Inc.

Received Nasdaq notice on Nov 23, 2021 for non-compliance with Listing Rule 5605 after appointing Michael Breen as Executive Chairman.
Breen resigned from Audit, Compensation, and Nominating Committees on Nov 23, 2021, triggering the deficiency.
Cure period runs until earlier of next annual shareholders' meeting or Nov 8, 2022 (or May 9, 2022 if meeting before).
Company is reviewing independent director candidates and expects to regain compliance within the cure period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.